Investigation into the mechanism of RNA polymerase I inhibition by the anticancer agent 9-hydroxyellipticine

Transcription by RNA polymerase 1 (Pol-1) is the main driving force behind ribosome biogensis, a fundamental cellular process that requires the coordinated transcription of all three nuclear polymerases. Increased Pol-1 transcription, and the concurrent increase in ribosome biogensis has been linked...

Full description

Bibliographic Details
Main Author:	Andrews, William John
Published:	Queen's University Belfast 2013
Subjects:	572.8845
Online Access:	http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.598029

id	ndltd-bl.uk-oai-ethos.bl.uk-598029
record_format	oai_dc
spelling	ndltd-bl.uk-oai-ethos.bl.uk-5980292015-03-20T04:54:10ZInvestigation into the mechanism of RNA polymerase I inhibition by the anticancer agent 9-hydroxyellipticineAndrews, William John2013Transcription by RNA polymerase 1 (Pol-1) is the main driving force behind ribosome biogensis, a fundamental cellular process that requires the coordinated transcription of all three nuclear polymerases. Increased Pol-1 transcription, and the concurrent increase in ribosome biogensis has been linked to the high rates of proliferation in many cancers. The ellipticine family contains a number of potent anticancer therapeutic agents with some having progressed to stage 1 and II clinical trial; however the mechanism by which these compounds works remain unclear.572.8845Queen's University Belfasthttp://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.598029Electronic Thesis or Dissertation
collection	NDLTD
sources	NDLTD
topic	572.8845
spellingShingle	572.8845 Andrews, William John Investigation into the mechanism of RNA polymerase I inhibition by the anticancer agent 9-hydroxyellipticine
description	Transcription by RNA polymerase 1 (Pol-1) is the main driving force behind ribosome biogensis, a fundamental cellular process that requires the coordinated transcription of all three nuclear polymerases. Increased Pol-1 transcription, and the concurrent increase in ribosome biogensis has been linked to the high rates of proliferation in many cancers. The ellipticine family contains a number of potent anticancer therapeutic agents with some having progressed to stage 1 and II clinical trial; however the mechanism by which these compounds works remain unclear.
author	Andrews, William John
author_facet	Andrews, William John
author_sort	Andrews, William John
title	Investigation into the mechanism of RNA polymerase I inhibition by the anticancer agent 9-hydroxyellipticine
title_short	Investigation into the mechanism of RNA polymerase I inhibition by the anticancer agent 9-hydroxyellipticine
title_full	Investigation into the mechanism of RNA polymerase I inhibition by the anticancer agent 9-hydroxyellipticine
title_fullStr	Investigation into the mechanism of RNA polymerase I inhibition by the anticancer agent 9-hydroxyellipticine
title_full_unstemmed	Investigation into the mechanism of RNA polymerase I inhibition by the anticancer agent 9-hydroxyellipticine
title_sort	investigation into the mechanism of rna polymerase i inhibition by the anticancer agent 9-hydroxyellipticine
publisher	Queen's University Belfast
publishDate	2013
url	http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.598029
work_keys_str_mv	AT andrewswilliamjohn investigationintothemechanismofrnapolymeraseiinhibitionbytheanticanceragent9hydroxyellipticine
_version_	1716787490694627328

Investigation into the mechanism of RNA polymerase I inhibition by the anticancer agent 9-hydroxyellipticine

Similar Items